{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:34:18Z","timestamp":1774611258093,"version":"3.50.1"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Col. Daniel Connelly Memorial Fund"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K22 CA234406"],"award-info":[{"award-number":["K22 CA234406"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The prognosis for patients with pancreatic ductal adenocarcinoma (PDAC) is poor. Secondary brain metastasis (Br-M) occurs in less than 1% of patients. Clinical characteristics and molecular alterations have not been characterized in this rare patients\u2019 subset.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and methods<\/jats:title>\n                  <jats:p>The Foundry software platform was used to retrospectively query electronic health records for patients with Br-M secondary to PDAC from 2005 to 2023; clinical, molecular, and overall survival (OS) data were analyzed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Br-M was diagnosed in 44 patients with PDAC. Median follow-up was 78 months; median OS from initial PDAC diagnosis was 47 months. Median duration from PDAC diagnosis to Br-M detection was 24 months; median OS from Br-M diagnosis was 3 months. At Br-M diagnosis, 82% (n\u2005=\u200536) of patients had elevated CA19-9. Lung was the most common preexisting metastatic location (71%) with Br-M, followed by liver (66%). Br-M were most frequently observed in the frontal lobe (34%, n\u2005=\u200515), cerebellar region (23%, n\u2005=\u200510), and leptomeninges (18%, n\u2005=\u20058). KRAS mutations were detected in 94.1% (n\u2005=\u200516) of patients who had molecular data available (n\u2005=\u200517) with KRASG12V being the most frequent subtype 47% (n\u2005=\u20058); KRASG12D in 29% (n\u2005=\u20055); KRASG12R in 18% (n\u2005=\u20053). Patients who underwent Br-M surgical resection (n\u2005=\u20055) had median OS of 8.6 months, while median OS following stereotactic radiosurgery only (n\u2005=\u200511) or whole-brain radiation only (n\u2005=\u200520) was 3.3 and 2.8 months, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Br-M is a late PDAC complication, resulting in an extremely poor prognosis especially in leptomeningeal disease. KRAS was mutated in 94.1% of the patients and the KRASG12V subtype was prevalent.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae182","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T04:29:13Z","timestamp":1721190553000},"source":"Crossref","is-referenced-by-count":4,"title":["Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2550-4837","authenticated-orcid":false,"given":"Mahmoud","family":"Yousef","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark W","family":"Hurd","sequence":"additional","affiliation":[{"name":"Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelrahman","family":"Yousef","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5472-5344","authenticated-orcid":false,"given":"Ethan B","family":"Ludmir","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwathy B","family":"Pillai","sequence":"additional","affiliation":[{"name":"Department of Hospital Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7675-3461","authenticated-orcid":false,"given":"Eugene J","family":"Koay","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sali","family":"Albarouki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Baylor College of Medicine , Houston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Wei","family":"Tzeng","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Snyder","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew H G","family":"Katz","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huamin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J","family":"Overman","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anirban","family":"Maitra","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubham","family":"Pant","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon G","family":"Smaglo","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A","family":"Wolff","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7066-9058","authenticated-orcid":false,"given":"Dan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"issue":"11","key":"2025031509011177400_CIT0001","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1056\/NEJMra1404198","article-title":"Pancreatic adenocarcinoma","volume":"371","author":"Ryan","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"2025031509011177400_CIT0002","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4251\/wjgo.v12.i2.173","article-title":"Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy","volume":"12","author":"Sarantis","year":"2020","journal-title":"World J Gastrointest Oncol"},{"issue":"10039","key":"2025031509011177400_CIT0003","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic cancer","volume":"388","author":"Kamisawa","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"2025031509011177400_CIT0004","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1053\/j.gastro.2020.10.007","article-title":"Worldwide burden of, risk factors for, and trends in pancreatic cancer","volume":"160","author":"Huang","year":"2021","journal-title":"Gastroenterology"},{"issue":"8","key":"2025031509011177400_CIT0005","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/cam4.459","article-title":"Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer","volume":"4","author":"Peixoto","year":"2015","journal-title":"Cancer Med"},{"issue":"3","key":"2025031509011177400_CIT0006","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.pan.2021.01.014","article-title":"The impact of different metastatic patterns on survival in patients with pancreatic cancer","volume":"21","author":"He","year":"2021","journal-title":"Pancreatology"},{"issue":"16","key":"2025031509011177400_CIT0007","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1002\/cncr.25940","article-title":"Gastrointestinal cancer and brain metastasis: a rare and ominous sign","volume":"117","author":"Go","year":"2011","journal-title":"Cancer"},{"issue":"3","key":"2025031509011177400_CIT0008","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1023\/A:1024337020884","article-title":"Nervous system involvement by pancreatic cancer","volume":"63","author":"Park","year":"2003","journal-title":"J Neurooncol"},{"issue":"2","key":"2025031509011177400_CIT0009","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.3390\/ijms14024163","article-title":"Brain metastasis in pancreatic cancer","volume":"14","author":"Lemke","year":"2013","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2025031509011177400_CIT0010","doi-asserted-by":"crossref","first-page":"a031435","DOI":"10.1101\/cshperspect.a031435","article-title":"Kras: The critical driver and therapeutic target for pancreatic cancer","volume":"8","author":"Waters","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"2025031509011177400_CIT0011","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","article-title":"Integrated genomic characterization of pancreatic ductal adenocarcinoma","volume":"32","author":"Cancer Genome Atlas Research Network","year":"2017","journal-title":"Cancer Cell"},{"issue":"7592","key":"2025031509011177400_CIT0012","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey PChang DKNones","year":"2016","journal-title":"Nature"},{"issue":"7477","key":"2025031509011177400_CIT0013","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(g12c) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"issue":"7781","key":"2025031509011177400_CIT0014","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(g12c) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"issue":"1","key":"2025031509011177400_CIT0015","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRASg12c inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov"},{"issue":"13","key":"2025031509011177400_CIT0016","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(g12c) inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"2025031509011177400_CIT0017","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12c-mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"2025031509011177400_CIT0018","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","article-title":"Efficacy of a small-molecule inhibitor of KrasG12d in immunocompetent models of pancreatic cancer","volume":"13","author":"Kemp","year":"2023","journal-title":"Cancer Discov"},{"issue":"1","key":"2025031509011177400_CIT0019","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41698-024-00505-0","article-title":"Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma","volume":"8","author":"Yousef","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"15_suppl","key":"2025031509011177400_CIT0020","doi-asserted-by":"crossref","first-page":"e18077","DOI":"10.1200\/JCO.2019.37.15_suppl.e18077","article-title":"Building a data foundation: How md anderson and palantir are partnering to accelerate research and improve patient care","volume":"37","author":"Alfaro-Munoz","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"2025031509011177400_CIT0021","doi-asserted-by":"crossref","first-page":"e23160","DOI":"10.1200\/JCO.2016.34.15_suppl.e23160","article-title":"Tackling \u201cbig data\u201d for accelerating cancer research","volume":"34","author":"Goldstein","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025031509011177400_CIT0022","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jmoldx.2016.09.011","article-title":"A targeted high-throughput next-generation sequencing panel for clinical screening of mutations, gene amplifications, and fusions in solid tumors","volume":"19","author":"Luthra","year":"2017","journal-title":"J Mol Diagn"},{"issue":"25","key":"2025031509011177400_CIT0023","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1200\/JCO.2014.60.4165","article-title":"Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials","volume":"33","author":"Meric-Bernstam","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025031509011177400_CIT0024","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"2025031509011177400_CIT0025","author":"Surveillance Research Program NCI","year":"2023"},{"issue":"4","key":"2025031509011177400_CIT0026","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","article-title":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the know your tumor registry trial","volume":"21","author":"Pishvaian","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"2025031509011177400_CIT0027","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"2025031509011177400_CIT0028","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/j.clcc.2018.01.009","article-title":"Brain metastases in pancreatic ductal adenocarcinoma: assessment of molecular genotype\u2013phenotype features\u2014an entity with an increasing incidence","volume":"17","author":"Emmet","year":"2018","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"2025031509011177400_CIT0029","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12029-014-9667-y","article-title":"CNS involvement in pancreatic adenocarcinoma: a report of eight cases from the johns hopkins hospital and review of literature","volume":"46","author":"Kumar","year":"2015","journal-title":"J Gastrointest Cancer"},{"issue":"1","key":"2025031509011177400_CIT0030","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"22","key":"2025031509011177400_CIT0031","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-cell receptor gene therapy in pancreatic cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"2025031509011177400_CIT0032","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific car t cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat Med"},{"issue":"10","key":"2025031509011177400_CIT0033","first-page":"e590","article-title":"Brain metastasis from pancreatic cancer: our experience and systematic review","volume":"166","author":"Frank","year":"2022","journal-title":"World Neurosurgery"},{"issue":"10","key":"2025031509011177400_CIT0034","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.3748\/wjg.v23.i10.1872","article-title":"Prognostic value of site-specific metastases in pancreatic adenocarcinoma: a surveillance epidemiology and end results database analysis","volume":"23","author":"Oweira","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"7","key":"2025031509011177400_CIT0035","first-page":"584","article-title":"Carcinoma of the pancreas and periampullary structures. Pattern of metastasis at autopsy","volume":"108","author":"Lee","year":"1984","journal-title":"Arch Pathol Lab Med"},{"issue":"9","key":"2025031509011177400_CIT0036","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.3390\/jcm8091402","article-title":"Lung metastases in patients with stage iv pancreatic cancer: prevalence, risk factors, and survival impact","volume":"8","author":"Liu","year":"2019","journal-title":"J Clin Med"},{"issue":"7578","key":"2025031509011177400_CIT0037","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nature15756","article-title":"Tumour exosome integrins determine organotropic metastasis","volume":"527","author":"Hoshino","year":"2015","journal-title":"Nature"},{"issue":"6","key":"2025031509011177400_CIT0038","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.devcel.2018.05.025","article-title":"Regulation of epithelial plasticity determines metastatic organotropism in pancreatic cancer","volume":"45","author":"Reichert","year":"2018","journal-title":"Dev Cell"},{"issue":"1","key":"2025031509011177400_CIT0039","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1186\/s12885-018-4679-9","article-title":"Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior","volume":"18","author":"Sahin","year":"2018","journal-title":"BMC Cancer"},{"issue":"19","key":"2025031509011177400_CIT0040","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.3390\/cancers14194963","article-title":"Molecular mechanisms driving the formation of brain metastases","volume":"14","author":"Campbell","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2025031509011177400_CIT0041","doi-asserted-by":"crossref","first-page":"e2228083","DOI":"10.1001\/jamanetworkopen.2022.28083","article-title":"Outcomes and molecular features of brain metastasis in gastroesophageal adenocarcinoma","volume":"5","author":"Tsai","year":"2022","journal-title":"JAMA Network Open"},{"issue":"4","key":"2025031509011177400_CIT0042","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/oncolo\/oyac273","article-title":"Brain metastases from biliary tract cancer: case series and clinicogenomic analysis","volume":"28","author":"Dodoo","year":"2023","journal-title":"Oncologist"},{"issue":"2","key":"2025031509011177400_CIT0043","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","article-title":"Integrated genomic characterization of pancreatic ductal adenocarcinoma","volume":"32","year":"2017","journal-title":"Cancer Cell"},{"key":"2025031509011177400_CIT0044","doi-asserted-by":"crossref","first-page":"103897","DOI":"10.1016\/j.ebiom.2022.103897","article-title":"Characterization of the genomic landscape in large-scale chinese patients with pancreatic cancer","volume":"77","author":"Zhang","year":"2022","journal-title":"EBioMedicine"},{"issue":"28","key":"2025031509011177400_CIT0045","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.23.00046","article-title":"Intracranial efficacy of adagrasib in patients from the krystal-1 trial with krasg12c-mutated non\u2013small-cell lung cancer who have untreated CNS metastases","volume":"41","author":"Negrao","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"2025031509011177400_CIT0046","doi-asserted-by":"crossref","first-page":"S1123","DOI":"10.1016\/j.jtho.2021.08.547","article-title":"P52.03 efficacy of sotorasib in kras p.G12c-mutated nsclc with stable brain metastases: a post-hoc analysis of codebreak 100","volume":"16","author":"Ramalingam","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"4","key":"2025031509011177400_CIT0047","doi-asserted-by":"crossref","first-page":"e60870","DOI":"10.1371\/journal.pone.0060870","article-title":"Somatic mutations in exocrine pancreatic tumors: association with patient survival","volume":"8","author":"Rachakonda","year":"2013","journal-title":"PLoS One"},{"issue":"14","key":"2025031509011177400_CIT0048","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1158\/1078-0432.CCR-09-0227","article-title":"Smad4 gene mutations are associated with poor prognosis in pancreatic cancer","volume":"15","author":"Blackford","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2025031509011177400_CIT0049","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s40792-022-01461-2","article-title":"A case of radical resection for brain metastases of pancreatic cancer after curative chemotherapy for para-aortic lymph node metastases","volume":"8","author":"Utsunomiya","year":"2022","journal-title":"Surg Case Rep"},{"issue":"11","key":"2025031509011177400_CIT0050","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/annonc\/mdi351","article-title":"Spectrum of breast cancer metastasis in brca1 mutation carriers: highly increased incidence of brain metastases","volume":"16","year":"2005","journal-title":"Ann Oncol"},{"issue":"6","key":"2025031509011177400_CIT0051","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/bjc.2014.418","article-title":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","volume":"111","author":"Golan","year":"2014","journal-title":"Br J Cancer"},{"issue":"12","key":"2025031509011177400_CIT0052","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/neuonc\/noaa228","article-title":"Penetrating the brain tumor space with DNA damage response inhibitors","volume":"22","author":"Bindra","year":"2020","journal-title":"Neuro Oncol"},{"issue":"3","key":"2025031509011177400_CIT0053","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.pan.2021.02.003","article-title":"Leptomeningeal disease in pancreas ductal adenocarcinoma: a manifestation of longevity","volume":"21","author":"O\u2019Connor","year":"2021","journal-title":"Pancreatology"},{"issue":"12","key":"2025031509011177400_CIT0054","first-page":"4599","article-title":"Long-term survival following resection of brain metastases from pancreatic cancer","volume":"31","author":"LEMKE","year":"2011","journal-title":"Anticancer Res"},{"key":"2025031509011177400_CIT0055","doi-asserted-by":"crossref","first-page":"bcr2018224354","DOI":"10.1136\/bcr-2018-224354","article-title":"Metastatic pancreatic adenocarcinoma presenting as an occipital haemorrhage","volume":"2018","author":"Ng","year":"2018","journal-title":"BMJ Case Rep"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/1\/oyae182\/58563019\/oyae182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/1\/oyae182\/58563019\/oyae182.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T09:01:53Z","timestamp":1742029313000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae182\/7715409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,17]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae182","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,7,16]]},"article-number":"oyae182"}}